This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, J. Articles by Zhang, L. Search for Related Content PubMed PubMed Citation Articles by Chen, J. Articles by Zhang, L.

Tachyplesin Activates the Classic Complement Pathway to Kill Tumor Cells

¹ Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia; ² National Cancer Institute, NIH, Bethesda, Maryland; ³ Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York; ⁴ Department of Pathology, Beijing General Hospital, Beijing, PR China; and ⁵ Key Laboratory of China Education Ministry on Cell Biology and Tumor Cell Engineering, Xiamen University, Fujian, PR China

Requests for reprints: Lurong Zhang, Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642-8647. Phone: 585-275-2985; Fax: 585-275-6337; E-mail: Lurong_Zhang{at}urmc.rochester.edu.

Tachyplesin is a small, cationic peptide that possesses antitumor properties. However, little is known about its action mechanism. We used phage display to identify a protein that interacted with tachyplesin and isolated a sequence corresponding to the collagen-like domain of C1q, a key component in the complement pathway. Their interaction was subsequently confirmed by both ELISA and affinity precipitation. Tachyplesin seemed to activate the classic complement cascade because it triggered several downstream events, including the cleavage and deposition of C4 and C3 and the formation of C5b-9. When TSU tumor cells were treated with tachyplesin in the presence of serum, activated C4b and C3b could be detected on tumor cells by flow cytometry, Western blotting, and confocal microscopy. However, this effect was blocked when the tumor cells were treated with hyaluronidase or a large excess of hyaluronan, indicating that hyaluronan or related glycosaminoglycans were involved in this process. Treatment of cells with tachyplesin and serum increased in membrane permeability as indicated by the ability of FITC-dextran to enter the cytoplasm. Finally, the combination of tachyplesin and human serum markedly inhibited the proliferation and caused death of TSU cells, and these effects were attenuated if the serum was heat-inactivated or if hyaluronidase was added. Taken together, these observations suggest that tachyplesin binds to both hyaluronan on the cell surface and C1q in the serum and activates the classic complement cascade, which damages the integrity of the membranes of the tumor cells resulting in their death.

This article has been cited by other articles:

				H. Sarig, S. Rotem, L. Ziserman, D. Danino, and A. Mor Impact of Self-Assembly Properties on Antibacterial Activity of Short Acyl-Lysine Oligomers Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4308 - 4314. [Abstract] [Full Text] [PDF]

				Y. Porat, K. Marynka, A. Tam, D. Steinberg, and A. Mor Acyl-Substituted Dermaseptin S4 Derivatives with Improved Bactericidal Properties, Including on Oral Microflora Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4153 - 4160. [Abstract] [Full Text] [PDF]